TY - JOUR
T1 - Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer
T2 - Findings from the ACCENT database
AU - McCleary, Nadine J.
AU - Meyerhardt, Jeffrey A.
AU - Green, Erin
AU - Yothers, Greg
AU - De Gramont, Aimery
AU - Van Cutsem, Eric
AU - O’Connell, Michael
AU - Twelves, Christopher J.
AU - Saltz, Leonard B.
AU - Haller, Daniel G.
AU - Sargent, Daniel J.
N1 - Publisher Copyright:
© 2013 by American Society of Clinical Oncology.
PY - 2013/7/10
Y1 - 2013/7/10
N2 - Purpose: Prior studies have suggested that patients with stage II/III colon cancer receive similar benefit from intravenous (IV) fluoropyrimidine adjuvant therapy regardless of age. Combination regimens and oral fluorouracil (FU) therapy are now standard. We examined the impact of age on colon cancer recurrence and mortality after adjuvant therapy with these newer options. Patients and Methods: We analyzed 11,953 patients age < 70 and 2,575 age ≥ 70 years from seven adjuvant therapy trials comparing IV FU with oral fluoropyrimidines (capecitabine, uracil, or tegafur) or combinations of fluoropyrimidines with oxaliplatin or irinotecan in stage II/III colon cancer. End points were disease-free survival (DFS), overall survival (OS), and time to recurrence (TTR). Results: In three studies comparing oxaliplatin-based chemotherapy with IV FU, statistically significant interactions were not observed between treatment arm and age (P interaction = .09 for DFS, .05 for OS, and .36 for TTR), although the stratified point estimates suggested limited benefit from the addition of oxaliplatin in elderly patients (DFS hazard ratio [HR], 0.94; 95% CI, 0.78 to 1.13; OS HR, 1.04; 95% CI, 0.85 to 1.27). No significant interactions by age were detected with oral fluoropyrimidine therapy compared with IV FU; noninferiority was supported in both age populations. Conclusion: Patients age ≥ 70 years seemed to experience reduced benefit from adding oxaliplatin to fluoropyrimidines in the adjuvant setting, although statistically, there was not a significant effect modification by age, whereas oral fluoropyrimidines retained their efficacy.
AB - Purpose: Prior studies have suggested that patients with stage II/III colon cancer receive similar benefit from intravenous (IV) fluoropyrimidine adjuvant therapy regardless of age. Combination regimens and oral fluorouracil (FU) therapy are now standard. We examined the impact of age on colon cancer recurrence and mortality after adjuvant therapy with these newer options. Patients and Methods: We analyzed 11,953 patients age < 70 and 2,575 age ≥ 70 years from seven adjuvant therapy trials comparing IV FU with oral fluoropyrimidines (capecitabine, uracil, or tegafur) or combinations of fluoropyrimidines with oxaliplatin or irinotecan in stage II/III colon cancer. End points were disease-free survival (DFS), overall survival (OS), and time to recurrence (TTR). Results: In three studies comparing oxaliplatin-based chemotherapy with IV FU, statistically significant interactions were not observed between treatment arm and age (P interaction = .09 for DFS, .05 for OS, and .36 for TTR), although the stratified point estimates suggested limited benefit from the addition of oxaliplatin in elderly patients (DFS hazard ratio [HR], 0.94; 95% CI, 0.78 to 1.13; OS HR, 1.04; 95% CI, 0.85 to 1.27). No significant interactions by age were detected with oral fluoropyrimidine therapy compared with IV FU; noninferiority was supported in both age populations. Conclusion: Patients age ≥ 70 years seemed to experience reduced benefit from adding oxaliplatin to fluoropyrimidines in the adjuvant setting, although statistically, there was not a significant effect modification by age, whereas oral fluoropyrimidines retained their efficacy.
UR - http://www.scopus.com/inward/record.url?scp=84883893403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883893403&partnerID=8YFLogxK
U2 - 10.1200/JCO.2013.49.6638
DO - 10.1200/JCO.2013.49.6638
M3 - Article
C2 - 23733765
AN - SCOPUS:84883893403
SN - 0732-183X
VL - 31
SP - 2600
EP - 2606
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 20
ER -